Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed)
About
This Notice of Funding Opportunity (NOFO) invites a single cooperative agreement application for the Resource Center for the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D). The purpose of CaRe-T1D is to support innovative, discovery and mechanistic research through the study of human cardiovascular (CV) tissue. This research seeks to better understand cardiovascular disease (CVD) in type 1 diabetes, highlight differences compared to type 2 diabetes, and ultimately guide the development of therapies to treat this major cause of morbidity and mortality for individuals with type 1 diabetes. To achieve these goals, the Resource Center will expand the CaRe-T1D biorepository of human CV tissue, further develop the data commons for data sharing and for artificial intelligence (AI) tools, coordinate the research activities of the investigative teams in the CaRe-T1D consortium, and make CaRe-T1D resources accessible to the broader research community. This NOFO is associated with the Special Diabetes Program (https://www. niddk. nih. gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks. This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite application(s) from eligible organization(s) to a.
The Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center is a federal funding opportunity designed to advance cardiovascular disease research in type 1 diabetes. This grant supports innovative discovery and mechanistic research through the study of human cardiovascular tissue, helping researchers better understand why cardiovascular disease affects individuals with type 1 diabetes differently than those with type 2 diabetes. The Resource Center will expand the CaRe-T1D biorepository of human cardiovascular tissue, develop advanced data commons for data sharing and artificial intelligence tools, coordinate research activities across investigative teams, and make resources accessible to the broader research community. This funding is part of the Special Diabetes Program, which focuses on prevention, treatment, and cure of type 1 diabetes and its complications through unique, innovative, and collaborative research consortia. Eligible organizations should be prepared to contribute significantly to cardiovascular research infrastructure, tissue banking, data management, and multi-institutional research coordination that will benefit the entire research community studying type 1 diabetes complications.
Funding Facts
● Applications openDeadline
September 30, 2026
Award Amount
Up to $1.5M
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Grant Amount
Up to $1.5M
Deadline
2026-09-30
Grant Type
federal
Application Cycle
Single Source Competition - Application Deadline September 30, 2026
Best For
Research institutions focused on type 1 diabetes cardiovascular disease research and biorepository management
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Only the following applicant is eligible to apply for this single source funding: University of Florida. Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not e
Frequently Asked Questions
Who is eligible for Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed)?
This is a single source funding opportunity with specific eligibility restrictions. According to the Notice of Funding Opportunity, the University of Florida is identified as an eligible applicant organization. Foreign organizations and non-domestic components of U.S. organizations are not eligible. For complete eligibility requirements, refer to Section III of the official NOFO or contact the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
How much funding does Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed) provide?
The funding range for this grant is between $0 and $1,500,000. The specific award amount may vary based on the scope of the proposed Resource Center continuation and available appropriations from the Special Diabetes Program. Contact NIDDK for information about typical funding levels for previous award cycles.
How do I apply for Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed)?
Applications must be submitted according to the requirements outlined in the official Notice of Funding Opportunity (NOFO). The application deadline is September 30, 2026. Applicants should review the complete NOFO at grants.nih.gov or the NIDDK website for detailed submission instructions, required forms, and proposal guidelines. Contact NIDDK program staff if you have questions about eligibility or the application process.
What can Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed) funding be used for?
Funding supports Resource Center operations including: expansion of the CaRe-T1D biorepository of human cardiovascular tissue; development and maintenance of data commons for data sharing; development of artificial intelligence tools for cardiovascular research; coordination of research activities across CaRe-T1D investigative teams; and making CaRe-T1D resources accessible to the broader research community. Clinical trial activities are not permitted under this funding mechanism.
Last updated: July 5, 2026